PMID- 36189258
OWN - NLM
STAT- MEDLINE
DCOM- 20221004
LR  - 20221005
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Aging-related features predict prognosis and immunotherapy efficacy in 
      hepatocellular carcinoma.
PG  - 951459
LID - 10.3389/fimmu.2022.951459 [doi]
LID - 951459
AB  - The aging microenvironment serves important roles in cancers. However, most 
      studies focus on circumscribed hot spots such as immunity and metabolism. Thus, 
      it is well ignored that the aging microenvironment contributes to the 
      proliferation of tumor. Herein, we established three prognosis-distinctive aging 
      microenvironment subtypes, including AME1, AME2, and AME3, based on aging-related 
      genes and characterized them with "Immune Exclusion," "Immune Infiltration," and 
      "Immune Intermediate" features separately. AME2-subtype tumors were characterized 
      by specific activation of immune cells and were most likely to be sensitive to 
      immunotherapy. AME1-subtype tumors were characterized by inhibition of immune 
      cells with high proportion of Catenin Beta 1 (CTNNB1) mutation, which was more 
      likely to be insensitive to immunotherapy. Furthermore, we found that CTNNB1 may 
      inhibit the expression of C-C Motif Chemokine Ligand 19 (CCL19), thus restraining 
      immune cells and attenuating the sensitivity to immunotherapy. Finally, we also 
      established a robust aging prognostic model to predict the prognosis of patients 
      with hepatocellular carcinoma. Overall, this research promotes a comprehensive 
      understanding about the aging microenvironment and immunity in hepatocellular 
      carcinoma and may provide potential therapeutic targets for immunotherapy.
CI  - Copyright (c) 2022 Hong, Su, Pan, Tian and Lei.
FAU - Hong, Ting
AU  - Hong T
AD  - Department of Radiation Oncology, Hunan Cancer Hospital and the Affiliated Cancer 
      Hospital of Xiangya School of Medicine, Central South University, Changsha, 
      China.
AD  - Department of Gynecology Oncology, Hunan Cancer Hospital and The Affiliated 
      Cancer Hospital of Xiangya School of Medicine, Central South University, 
      Changsha, China.
FAU - Su, Wei
AU  - Su W
AD  - Department of Medical Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
FAU - Pan, Yitong
AU  - Pan Y
AD  - Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, 
      Chinese Academy of Sciences (CAS), Beijing, China.
FAU - Tian, Chenxi
AU  - Tian C
AD  - Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, 
      Chinese Academy of Sciences (CAS), Beijing, China.
FAU - Lei, Guang
AU  - Lei G
AD  - Department of Radiation Oncology, Hunan Cancer Hospital and the Affiliated Cancer 
      Hospital of Xiangya School of Medicine, Central South University, Changsha, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220915
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Chemokines)
RN  - 0 (Ligands)
SB  - IM
MH  - Aging
MH  - *Carcinoma, Hepatocellular/genetics/metabolism/therapy
MH  - Chemokines/therapeutic use
MH  - Humans
MH  - Immunotherapy
MH  - Ligands
MH  - *Liver Neoplasms/genetics/metabolism/therapy
MH  - Prognosis
MH  - Tumor Microenvironment
PMC - PMC9521435
OTO - NOTNLM
OT  - CTNNB1 mutation
OT  - aging microenvironment subtypes
OT  - hepatocellular carcinoma (HCC)
OT  - immunological therapy
OT  - prognostic model
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/04 06:00
MHDA- 2022/10/05 06:00
PMCR- 2022/01/01
CRDT- 2022/10/03 05:18
PHST- 2022/05/24 00:00 [received]
PHST- 2022/08/03 00:00 [accepted]
PHST- 2022/10/03 05:18 [entrez]
PHST- 2022/10/04 06:00 [pubmed]
PHST- 2022/10/05 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.951459 [doi]
PST - epublish
SO  - Front Immunol. 2022 Sep 15;13:951459. doi: 10.3389/fimmu.2022.951459. eCollection 
      2022.